Funding awarded for antimalarial drugs

The National Institutes of Health have awarded $718,136 in funding to the University of California San Francisco in collaboration with Anacor Pharmaceuticals to discover and optimize oxaboroles as antimalarial drugs.
The grant provides support for the period beginning September 30 and ending September 29, 2012. Anacor's work with UCSF to discover new antimalarial agents is in addition to the company's collaboration with Medicines for Malaria Venture to develop AN3661, a novel boron-based antimalarial compound that is currently in clinical trials.
Anacor is also working on a funded research program with MMV to discover backup compounds for AN3661. Anacor and MMV plan to conduct Phase 1 and Phase 2 proof of concept studies for AN3661, at which point GlaxoSmithKline will have an option to license the program on an exclusive worldwide basis.
Malaria is a treatable and preventable infectious disease that is caused by a parasite transmitted by mosquitoes that kills almost one million people each year. There are antimalarial medications currently available, but the malaria parasite is developing resistance to them, rendering current drugs less effective and increasing the demand for innovative new therapies.
Anacor is a biopharmaceutical company that focuses on discovering, developing and commercializing novel small-molecule therapeutics that are derived from its boron chemistry platform.

Organizations in this Story

National Institutes of Health

Want to get notified whenever we write about National Institutes of Health ?
Next time we write about National Institutes of Health, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.